Drug Trial Radar · NCT07942168
Doxorubicin Plus Dacarbazine Versus Doxorubicin Alone as First-Line Therapy for Metastatic or Recurrent Uterine Leiomyosarcoma
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Jan 24, 2023
Primary completion
Jan 2027
Study completion Jan 2027
Sponsor
- Lead sponsor
- Blokhin's Russian Cancer Research CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn whether adding dacarbazine to doxorubicin works better than doxorubicin alone as the first drug treatment for women with uterine leiomyosarcoma that is metastatic or has come back after surgery. A total of 100 participants will be randomly assigned to receive either doxorubicin alone or doxorubicin plus dacarbazine for up to 6 cycles of 21 days each. Researchers will compare how many participants are alive without disease progression 1 year after the start of treatment.
Conditions
- Leiomyosarcoma
- Uterine Leiomyosarcoma
Interventions
DoxorubicinDrug
Doxorubicin 75 mg/m² IV infusion, Day 1, Q3W for 6 cycles in first line
DoxorubicinDrug
Doxorubicin 15 mg/m²/day IV 24-h continuous infusion, Days 1-4, Q3W for 6 cycles in first line
dacarbazineDrug
Dacarbazine 187.5 mg/m²/day IV 24-h continuous infusion, Days 1-4, Q3W for 6 cycles in first line
Primary outcomes
What the sponsor says the trial is designed to measure.
- 1-year progression-free survival (PFS)Time frame: Time from enrollment to disease progression or relapse or death due to any cause, or data cut-off date at 1 year, whichever occured first (up to ~12 months)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" оf the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO)
Moscow, Russia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.